Skip to main content
. 2017 Aug 1;9(9):1183–1197. doi: 10.15252/emmm.201607485

Figure 3. Indication, age, CAR generation, and targeted antigen in clinical trials.

Figure 3

(A) Solid tumors versus tumors of the hematopoietic and lymphoid system. The number of ongoing trials (dark blue bar) is compared to the number of non‐active trials (light blue bar). (B) Patient age distribution for solid tumors (light blue bars) and hematological malignancies (dark blue bars). (C) Generation of the CAR constructs applied. (D) Targeted antigens separated for tumors of hematopoietic or lymphoid origin (upper panel) and for solid tumors (lower panel).